Elicio Therapeutics announced that the Phase 2 AMPLIFY-7P study of ELI-002 7P in adjuvant pancreatic cancer did not meet its primary endpoint of disease-free survival (DFS) in the overall intent-to-treat population. However, the company attributes this failure to an imbalance in high-risk patients with residual disease (R1 resection) in the treatment arm. In a post-hoc analysis of patients with complete tumor resection (R0), the peptide vaccine demonstrated a statistically significant improvement in DFS and a strong correlation between mutant KRAS-specific T cell responses and survival.